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Irinotecan and cisplatin demonstrated promising outcomes in extensive-stage small-cell lung cancer. According to the dosage and
schedule of irinotecan, efficacy and toxicity profiles showed subtle differences. This study was designed to evaluate efficacy and
toxicity of 3-week schedule of irinotecan/cisplatin in patients with previously untreated extensive-stage small-cell lung cancer. The
primary objective was to evaluate response rate and secondary objectives were overall survival and progression-free survival. Patients
with previously untreated extensive-stage small-cell lung cancer were enrolled. Irinotecan 65mgm
 2 was administered on days 1 and
8 and cisplatin 60mgm
 2 on day 1. Treatment was repeated every 3 weeks. Seven out of 54 patients (13.0%) had complete
response, and partial response was observed in 33 (61.1%). The overall response rate was 74.1% (95% CI; 62.0–82.2%). Stable
disease was observed in eight (14.8%) and no progressive disease was observed. After a median follow-up duration of 28.7 months,
the median overall survival and progressive-free survival were 13.6 and 6.5 months, respectively. Major grade 3/4 toxicities were
neutropenia (50.0%), anorexia (42.6%), diarrhoea (29.6%), fatigue (29.6%) and vomiting (13.0%). There was one treatment-related
death owing to pneumonia. Three-week schedule of irinotecan/cisplatin showed effective antitumour activity and moderate toxicities
in patients with previously untreated extensive-stage small-cell lung cancer.
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Lung cancer is the leading cause of cancer-related deaths in
Western countries (Jemal et al, 2004), and also in Korea (Shin et al,
2004). The proportion of histologic diagnosis with small-cell lung
cancer (SCLC) in the United States is approximately 15% of
patients with lung cancer (Jemal et al, 2004), and more than half
of these patients are diagnosed with extensive-stage disease.
Incidence of SCLC had paralleled trends in cigarette smoking,
and smoking prevalence for the adult population is relatively high
in Korea. During the last decade, most patients with extensive-
stage SCLC (ES-SCLC) have been treated with etoposide and
platinum resulting in a median survival of 8–10 months (Roth
et al, 1992). Although several trials of platinum-based combination
chemotherapy were performed, it failed to show a superiority to
combination of etoposide and cisplatin (EP) (Mavroudis et al,
2001; Sundstrom et al, 2002).
Irinotecan, which inhibits the function of topoisomerase I in
cancer cells, demonstrated synergism and non-cross resistance
when combined with platinum agents (Fukuda et al, 1996; Masuda
et al, 1996). Kudoh et al (1998) reported that combination
chemotherapy of irinotecan and cisplatin (IP) in patients with
SCLC showed a promising response rate of 84 with 29% of
complete responses and median survival over 13 months. Since
then, several phase II/III trials of irinotecan-based combination
chemotherapy with different dose and schedule were performed
with varying results in SCLC patients (Noda et al, 2002; Kudoh
et al, 2005; Hanna et al, 2006; Kinoshita et al, 2006; Schmittel et al,
2006). In a previous phase III trial conducted by a Japanese group,
patients were treated with 60mgm
 2 of cisplatin on day 1 and
60mgm
 2 of irinotecan on days 1, 8, and 15 every 4 weeks, and
showed a good median survival of 12.8 months. However, only
80.4% of planned dose of irinotecan was administered and the day-
15 irinotecan was omitted in 50% of patients owing to toxicities
(Noda et al, 2002). Another phase III trial performed in the West
tested 65mgm
 2 of irinotecan on days 1 and 8 every 3 weeks in
ES-SCLC patients, and showed rather lower median survival of
9.3 months (Hanna et al, 2006) compared with the Japanese trial,
suggesting possible ethnic and pharmacogenomic differences
between the two study populations.
Based on these results, we conducted a phase II study using
irinotecan 65mgm
 2 on days 1 and 8, and cisplatin 60mgm
 2 on
day 1 schedule in chemotherapy-naı ¨ve ES-SCLC patients to
evaluate the efficacy and safety of the regimen in Korean patients.
PATIENTS AND METHODS
Patients’ eligibility
Patients with previously untreated ES-SCLC were enrolled. Patients
were eligible if they had (1) histologically confirmed small-cell
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scarcinoma; (2) extensive-stage disease; (3) Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of p3; (4) age
over 18 years old; (5) adequate haematologic parameters
(haemoglobin X9.0gdl
 1, absolute neutrophil count X1500ml
 1,
platelet count X100000ml
 1), renal functions (serum creatinine
p1.5mgdl
 1 or calculated creatinine clearance by Cockroft
formula X50mlmin
 1), and hepatic function (aspartate amino-
transferase, alanine aminotransferase p3  upper limits of
normal, total bilirubin p2  upper limits of normal); (6) at least
one bi-dimensionally measurable lesion according to the WHO
criteria (Miller et al, 1981); (7) absence of active infection; (8) no
prior chemotherapy, radiotherapy, or surgery for the disease; (9)
no history of myocardial infarction in the last 6 months before
the study entry; (10) no uncontrolled congestive heart failure or
significant arrhythmia; and (11) no prior second primary cancer,
except for cervix cancer in situ or skin cancer. Patients with brain
metastases were allowed provided that there were no significant
neurologic symptoms or signs. All patients provided written
informed consent before they entered the study. This protocol was
approved by the institutional review board at Samsung Medical
Center.
Treatment and dose modification
Patients were treated with irinotecan 65mgm
 2 on days 1 and 8,
and cisplatin 60mgm
 2 on day 1. Treatment cycles were repeated
every 3 weeks until the maximum six cycles initially planned,
documented disease progression, unacceptable toxicity, or pa-
tient’s refusal. Cisplatin was given with adequate hydration of 2l
of intravenous fluid to protect renal functions and with diuretics
if needed to control volume status. Cholinergic symptoms that
occurred during or within 1h after irinotecan administration were
treated with atropine (0.3mg or as needed). Loperamide was
provided as therapy for prophylaxis of delayed diarrhoea. A 5-
hydroxytryptamine type-3 receptor antagonist was given as emesis
prophylaxis before drug administration.
Application of chemotherapy was delayed by one or two weeks
until haematologic recovery of absolute neutrophil count
X1500ml
 1 and platelet X100000ml
 1. Administration of irino-
tecan was omitted on day eight if grade 2 or 3 diarrhoea occurred,
and subsequent cycles were allowed when the diarrhoea recovered
to baseline or gradep1. The dose of irinotecan in subsequent
cycles was reduced by 25% from the planned dose if there were any
grade 4 hematologic toxicities lasting more than 7 days, Xgrade 3
haematologic toxicities with febrile episode, or bleeding-associated
thrombocytopenia. Treatment was discontinued in patients with
grade 4 diarrhoea. The dose of cisplatin in subsequent cycles was
reduced by 25% from the planned dose if there were grade 4
haematologic toxicities or if grade 2 renal toxicity. In the presence
of grade 3 or 4 non-haematologic toxicity (except nausea,
vomiting, and alopecia), the treatment was postponed until
resolution of the toxicity and then both drug doses were reduced
by 25% for the next cycle. Once a dose reduction was required,
re-escalation of dose was not allowed.
Assessment of efficacy and toxicity
The following pretreatment evaluations were performed within 2
weeks before study entry: a full medical history and physical
examination, complete blood cell count with differentials, chemis-
try profiles, urinalysis, and performance status evaluation. Chest
X-rays, chest and upper abdominal computed tomography (CT)
scans, brain magnetic resonance imaging, radionuclide bone scan
and any other diagnostic procedures as clinically indicated were
performed within 4 weeks before enrollment. During treatment,
a limited history taking, physical examination, assessment of
toxicity, complete blood cell count with differentials, blood
chemistry and chest X-rays were performed every 3 weeks before
each cycle. Appropriate imaging studies including CT scans of
chest and upper abdomen were performed every two cycles (6
weeks) to assess treatment response, and sooner if needed for
documentation of disease progression. Objective tumour responses
were assessed according to the WHO criteria (Miller et al, 1981).
Complete response (CR) was defined as the disappearance of all
known disease for at least 4 weeks with no new lesion appearing.
Partial response (PR) referred to an at least 50% decrease in the
sum of the products of bidimensional diametres lasting for at least
4 weeks without the appearance of new lesions. Stable disease (SD)
was defined as failure to observe a PR or CR, no progressive or new
lesions were observed for at least 4 weeks. Progressive disease (PD)
was defined as a 25% or greater increase in the sum of the products
of bidimensional diameters of any measurable lesion or the
appearance of new lesions. All enrolled patients were included
in the intention-to-treat analysis of efficacy. Response rate was
calculated as the ratio of the number of patients who achieved
complete or partial responses to the number of enrolled patients.
Overall survival (OS) and progression-free survival (PFS) were
calculated from the start of therapy until death and progression,
respectively, or until last follow-up. Toxicities were monitored
according to the National Cancer Institute Common Toxicity
Criteria (NCI-CTC) scale version 3.0.
Statistical consideration
The sample size was calculated according to Simon’s two-stage
optimal design (Simon, 1989). A targeted objective response rate of
80% versus an objective response rate of no interest of 60% with a
power of 0.90 at a one-sided significance level of 0.05 was chosen,
and accrual of 45 assessable patients was projected. In the initial
stage, 18 evaluable patients were to be entered into the study and
evaluated for response. If there were 4 11 responses, accrual was
to be terminated. If X11 responses were observed in the first stage,
then 27 additional patients were to be entered in the second stage
to achieve a target sample size of 45 evaluable patients. Assuming
that 10% of patients were inassessable, at least a total of 50 patients
were planned to be accrued for this study. All patients who
received at least one course of therapy were considered assessable
for toxicity, and all eligible patients who received at least one cycle
of therapy were included for survival estimation. Descriptive
statistics were reported as proportions and medians. OS and PFS
were assessed by the Kaplan–Meier method and the 95%
confidence interval (95% CI) for the median time to event was
computed.
RESULTS
Patient characteristics
Between November 2002 and January 2005, 54 patients were
enrolled and their clinical characteristics are shown in Table 1. The
median age was 64 years (range, 47–78 years), 49 patients (90.7%)
were male and five (9.3%) were female. Forty patients (74.1%) had
ECOG PS of 0–1, whereas 14 patients (25.9%) had ECOG PS of 2 or
3. The most common sites of metastasis were lymph nodes (40/54,
74.1%) and brain metastasis was observed in 17 patients (31.5%) at
the time of enrollment. Median serum lactate dehydrogenase
(LDH) level at initial diagnosis was 408IUl
 1 (range, 225–1566).
Drug administration
Drug administration and relative dose intensity are shown in
Table 2. The median number of cycles to be administered was four
(range 1–6 cycles), and 24 (44.4%) patients completed the planned
six cycles of chemotherapy. Treatment was delayed for a median of
2 weeks in 109 out of subsequent 223 cycles (48.9%). The most
common cause for delayed administration was neutropenia (58
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scycles, 53.3%). Twenty-two cycles (9.9%) required dose reductions
mainly due to neutropenia and diarrhoea. The delivered dose
intensity (DI) was 17.4mgm
 2week
 1 (87.0% of planned dose) for
cisplatin and 36.6mgm
 2week
 1 (84.5% of planned dose) for
irinotecan.
Response
Forty-eight (88.9%) of 54 patients were evaluable for responses. Six
patients were not evaluable, but were included in the intent-to-
treat analysis. Two patients refused to receive chemotherapy after
first cycle of the regimen and were lost to follow-up, one patient
was referred to another hospital, one patient was dropped out after
first dose of the regimen owing to poor performance status, one
patient underwent operation for gastric ulcer perforation, and
there was one treatment-related death.
The overall response rate was 74.1% (95% CI; 62.0—82.2%),
with a complete response rate of 13% (Table 3). SD was observed
in eight patients (14.8%) on initial assessment of response.
Survival
All 54 patients were included in the survival analysis on an intent-
to-treat basis. The OS and PFS of patients in this study is shown in
Figure 1. After the median follow-up duration of 28.7 months
(range, 10.9–45.0 months), the median overall survival was 13.6
months (95% CI, 10.7–15.5 months) and 1 year survival rate was
53.1%. The median PFS was 6.5 months (95% CI, 5.1–7.9 months)
and 1 year PFS was 10.5%.
Toxicities
All patients were evaluable for toxicities, and grade 3 or 4 toxicities
observed during treatment are listed in Table 4. Haematologic
toxicity was most prevalent in this study. Grade 3 or 4 neutropenia
occurred in 27 (50.0%) of 54 patients. Grade 3 or 4 anaemia and
Table 1 Patient characteristics
No. of patients %
Characteristics 54 100
Age, years (range) Median 64 (47–78)
Sex
Male 49 90.7
Female 5 9.3
ECOG PS
0 2 3.7
1 38 70.4
2 10 18.5
3 4 7.4
No. of distant metastatic sites
0 9 16.7
1 20 37.0
2 14 25.9
X3 11 20.4
Metastatic sites
Lymph nodes 40 74.1
Brain 17 31.5
Bone 16 29.6
Pleural effusion or seeding 16 29.6
Liver 14 25.9
Adrenal glands 11 20.4
Initial LDH (IUl) levels Median 408 (225–1566)
ECOG¼Eastern Cooperative Oncology Group; LDH¼lactate dehydrogenase;
PS¼performance status.
Table 2 No. of chemotherapy cycles and delivered actual dose
Cycles
No. of patient
(%)
1 7 (13.0)
2 9 (16.7)
3 4 (7.4)
4 8 (14.8)
5 2 (3.7)
6 24 (44.4)
Delivered dose/
planned dose
(mgm
 2week
 1)
% of planned dose
Cisplatin 17.4/20.0 87.0
Irinotecan 36.6/43.3 84.5
Table 3 Objective responses
Tumour response (n¼54) No. of patients %
Complete response* 7 13.0
Partial response* 33 61.1
Stable disease 8 14.8
Progressive disease 0 0
Not evaluable 6 11.1
*Overall response rate: 74.1% (95% CI, 62.0–86.2).
Overall survival (months)
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Progression-free survival (months)
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1.0
0.8
0.6
0.4
0.2
Median PFS – 6.5 months
Figure 1 OS and PFS of the all patients.
Three-week schedule of irinotecan and cisplatin for ES-SCLC
YS Hong et al
1650
British Journal of Cancer (2006) 95(12), 1648–1652 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sthrombocytopenia were observed in two (3.7%) of 54 patients,
respectively. Most significant Xgrade 3 non-haematologic toxicity
was anorexia (n¼23, 42.6%). Grade 3 or 4 diarrhoea occurred in
16 (29.6%) patients, with grade 2 diarrhoea in seven (13.0%)
patients and grade 1 diarrhoea in 22 (40.7%) patients. In addition,
24 (44.4%) patients showed grade 2 alopecia and seven (13.0%)
showed grade 2 neuropathy. There was one treatment-related
death. That patient was a 51-year-old male with ECOG perfor-
mance status score of 3, and had brain metastasis at initial
presentation of disease. He developed neutropenic sepsis with
pneumonia caused by Streptococcus pneumoniae on day 19 and
died of aggravation of pneumonia on day 26 of the first cycle of
chemotherapy despite recovery from neutropenia.
Salvage chemotherapy
Of 55 patients, 24 patients (43.6%) were treated with systemic
chemotherapy as second-line treatment, and 22 patients were
evaluable for treatment responses. Salvage regimens included
etoposide and carboplatin (11/24, 45.8%), EP (10/24, 41.7%), oral
etoposide and carboplatin (2/24, 8.3%), and paclitaxel and
ifosfamide (1/24, 4.2%). By intent-to-treat analysis, overall
response rate of salvage treatment was 37.5% (95% CI, 18.1–
56.9%) with one CR and eight PR. SD and PD were observed in
four patients (16.7%) and nine patients (37.5%), respectively.
Median time to progression (TTP) was 3.4 months (1.0–20.0
months) in all 24 patients and median duration of response was
3.6 months (1.6–19.8 months) in responders. We defined chemo-
sensitive relapse as PD was noted after 3 months of maximal
response, and primary refractory disease as initial maximal
response was SD, or PD was noted within 3 months of maximal
response. As our definition, 17 patients (17/24, 70%) showed
chemo-sensitive relapse, and seven patients (7/24, 30%) showed
primary refractory disease. In 17 patients with chemo-sensitive
relapse, responses to second-line chemotherapy were observed
in five patients (29.4%, with one CR and four PR.), SD in three
patients (17.6%), and PD in seven patients (41.2%). Two of 17
patients with chemo-sensitive relapse were inevaluable. In seven
patients with primary refractory disease, response to second-line
chemotherapy was observed in four patients (57.1%, with zero CR
and four PR), SD in one patient (14.3%), and PD in two patients
(28.6%). Response differences in these two groups did not show
statistical significance (P¼0.531).
DISCUSSION
For treatment for extensive-stage SCLC, combination chemother-
apy with EP has been the standard regimen since the last decade.
However, combination chemotherapy with IP came into the
spotlight after the Japanese phase II trial in 1998 (Kudoh et al,
1998). In 1998, Kudoh et al (1998) reported 84% of overall
response rate with 29% of complete response and 13 months of
median OS in patients with extensive-stage SCLC. In this trial,
irinotecan was administrated at 60mgm
 2 on days 1, 8 and 15
repeated every 3 weeks. In this dose and schedule of irinotecan,
grade 3 or 4 haematologic toxicities were exceedingly frequent with
77% of neutropenia, 45% of leucopenia. Despite high incidence of
haematologic toxicities, this study was the first to report median
survival that exceeds 1 year in ES-SCLC (Kudoh et al, 1998).
The promising preliminary results led to several irinotecan-
based phase II and III trials in patients with SCLC. Two most
representative phase III trials were published in 2002 and 2006,
respectively (Noda et al, 2002; Hanna et al, 2006). In 2002, Noda
et al (2002), reported that combination with irinotecan and
cisplatin (IP) was superior to that of EP in terms of response rates
and OS (65%, 12.8 months vs 52%, 9.4 months, P¼0.002) for the
patients with ES-SCLC. Although IP seemed more effective than
EP, the toxicities were higher in the IP arm with 65.3% of the
patients with grade 3/4 neutropenia and 26.7% with grade 3/4
diarrhoea. In this trial, irinotecan was administered with
60mgm
 2 on days 1, 8 and 15 every 4 weeks in combination
with 60mgm
 2 of cisplatin on day one, and the relative dose
intensity was 80.4% of the planned dose. Most recently, however,
Hanna et al (2006) reported IP did not show survival benefit
compared with EP (9.3 vs 10.2 months, P¼0.74). This trial
adopted 65mgm
 2 of irinotecan on days 1 and 8 every 3 weeks
schedule in combination with 30mgm
 2 of cisplatin on day 1 and
8, and showed lower overall response rate of 48% and shorter
median OS of 9.3 months compared with previous trial of Noda
et al (2002), in IP group. The toxicities seemed significantly lower
than previous trial with only 36.2% of patients experiencing grade
3/4 neutropenia in IP group (Hanna et al, 2006).
In this study, irinotecan was administered at 65mgm
 2 on days
1 and 8, combined with 60mgm
 2 of cisplatin on day 1 in a 3-week
schedule; thus, the dosages would be in the medium range as
compared to those used in previous two trials. This regimen
showed 74.1% of response rate and 13.6 months of median OS in
the same patient population. It surpasses the results of Kudoh et al
(1998) in median OS over 13 months, and showed higher response
rates than that of equal dosage of irinotecan (Hanna et al, 2006).
These results are very encouraging and superior to other trials with
similar irinotecan dosages and schedules. Grade 3/4 toxicities were
50% in neutropenia and 29.6% in diarrhoea, and were comparable
with previous other trials (Kudoh et al, 1998; Noda et al, 2002;
Hanna et al, 2006; Kinoshita et al, 2006). However, one treatment-
related death was observed in this trial. In the present study, four
patients (7.4%) had initial poor performance status of ECOG score
3 (Table 1). One patient died during chemotherapy as previously
noted, another two patients could not complete the planned
treatment owing to toxicities. Only one patient could receive
scheduled chemotherapy and showed response of stable disease.
As the SCLC is one of the most chemosensitive tumour types,
patients with poor performance status (PS X3) who are not
usually included in clinical trials of other tumour types had often
been included in some trials. The present study also included a few
patients with poor PS who, however, did not do so well with this
treatment as mentioned above. Therefore, special cautions need
to be exerted for patients with poor performance status in future
trials. Given the considerable toxicities and the median number of
cycles to be administered was four cycles, one may also need to
consider to shorten the treatment cycles to four from six in future
trials.
Irinotecan is metabolised by carboxylesterase to an active
metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). SN-38 is
then further metabolised in the liver by uridine diphosphate-
glucuronosyltransferases (UGTs) to an inactive metabolite, SN-38
Table 4 Toxicity profiles
Grade 3 Grade 4
No. of patients % No. of patients %
Hematologic toxicities
Neutropenia 18 33.3 9 16.7
Thrombocytopenia 0 0.0 2 3.7
Anaemia 2 3.7 0 0.0
Febrile neutropenia 7 13.0 1 1.9
Nonhematologic toxicities
Anorexia 22 40.7 1 1.9
Diarrhoea 15 27.7 1 1.9
Fatigue 15 27.7 1 1.9
Nausea/vomiting 7 13.0 0 0.0
Stomatitis 5 9.6 0 0.0
Constipation 4 7.4 0 0.0
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sglucuronide (SN-38G) (Mathijssen et al, 2001). This glucuronida-
tioin is the major route of detoxification of irinotecan, thus
inherited differences in irinotecan metabolism may have an
important influence on the pharmacokinetics and toxicity of this
drug. Han et al (2006) reported the UGT1A polymorphisms could
predict treatment outcomes and toxicities of irinotecan in Korean
patients. In this report, patients with homozygote of UGT1A1*6
allele had shorter PFS and more irinotecan-related toxicities. Six of
81 Korean patients (7.4%) had phenotype of UGT1A1*6 homo-
zygosity. Another phenotype associated with low tumour re-
sponses and high irinotecan-related toxicity is UGT1A1*28, and it
is highly prevalent in Caucasian individuals with reported
frequencies of 0.29–0.47 (Bosma et al, 1995; Premawardhena
et al, 2003), whereas it has much lower frequency in Asians (0.08–
0.19) (Yamamoto et al, 1998). In Korean report, the frequency of
UGT1A1*28 was 0.07 (Han et al, 2006). Therefore, it could be
explained that ethnic differences might be involved in discrepant
results in terms of efficacy and toxicity of irinotecan.
Given the similar schedule and dosage of irinotecan and
cisplatin combination chemotherapy in the trial performed by
Hanna et al (2006) compared with our study, higher response rate
(74.1 vs 48%) and longer median survival (13.6 vs 9.3 months) was
observed in our study. However, grade 3 or 4 toxicities were more
common in our study; neutropenia (50 vs 36.2%), febrile
neutropenia (14.9 vs 3.7%), and diarrhoea (29.6 vs 21.3%). Even
though the difference in dose and administration schedule, as well
as disease characteristics might be plausible explanations of the
disparities of outcome and toxicities between the two trials, it
might be largely attributable to the pharmacogenomic/ethnic
differences as was previously discussed by Hanna et al (2006),
Further study with UGT1A polymorphism in this population will
be needed.
In conclusion, our results suggest that 3-week schedule of
irinotecan (65mgm
 2, on days 1 and 8) and cisplatin (60mgm
 2,
on day 1) showed comparable results in terms of response rate,
survival, and toxicity with the 4-week schedule of JCOG.
Considering toxicity and convenience, 3-week schedule of
irinotecan and cisplatin can be a reasonable option in the
treatment of patients with ES-SCLC in Korea, which, however,
requires further study in Caucasian population.
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